Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease
Authors: Elisabetta Patorno, Phyo T. Htoo, Robert J. Glynn, Sebastian Schneeweiss, Deborah J. Wexler, Ajinkya Pawar, Lily G. Bessette, Kristyn Chin, Brendan M. Everett, Seoyoung C. Kim
Journal: Annals of Internal Medicine (2022)

LettersJanuary 2022Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular DiseaseElisabetta Patorno, MD, DrPH, Phyo T. Htoo, MD, PhD, Robert J. Glynn, ScD, PhD, Sebastian Schneeweiss, MD, ScD, Deborah J. Wexler, MD, MSc, Ajinkya Pawar, PhD, Lily G. Bessette, BS, Kristyn Chin, BS, Brendan M. Everett, MD, MPH, Seoyoung C. Kim, MD, ScDElisabetta Patorno, MD, DrPHBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, Phyo T. Htoo, MD, PhDBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, Robert J. Glynn, ScD, PhDBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, Sebastian Schneeweiss, MD, ScDBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, Deborah J. Wexler, MD, MScMassachusetts General Hospital Diabetes, Center, Harvard Medical School, Boston, Massachusetts, Ajinkya Pawar, PhDBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, Lily G. Bessette, BSBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, Kristyn Chin, BSBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, Brendan M. Everett, MD, MPHBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, Seoyoung C. Kim, MD, ScDBrigham and Women's Hospital and Harvard Medical School, Boston, MassachusettsAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L21-0709 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:The Editors have asked that we clarify the conclusions of our abstract. Our study found that, compared with use of GLP-1 RAs, use of SGLT2 inhibitors was associated with a reduction in the relative risk for hospitalization for heart failure among patients with T2D with and without CVD. However, there was a greater reduction in the absolute risk for this outcome associated with the use of SGLT2 inhibitors than with GLP-1 RAs among patients with CVD compared with those without CVD. Author, Article, and Disclosure InformationAffiliations: Brigham and Women's Hospital and Harvard Medical School, Boston, MassachusettsMassachusetts General Hospital Diabetes, Center, Harvard Medical School, Boston, Massachusetts* Drs. Everett and Kim contributed equally to this work and should be considered as co-senior authors.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M21-0893. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease Elisabetta Patorno , Phyo T. Htoo , Robert J. Glynn , Sebastian Schneeweiss , Deborah J. Wexler , Ajinkya Pawar , Lily G. Bessette , Kristyn Chin , Brendan M. Everett , and Seoyoung C. Kim Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease Mei Qiu Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease Lurit Bepo , Anil N. Makam , and Oanh Kieu Nguyen Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease Elisabetta Patorno , Phyo T. Htoo , Brendan M. Everett , and Seoyoung C. Kim Metrics January 2022Volume 175, Issue 1Page: W4-W5KeywordsCardiovascular diseasesCohort studiesDrugsHeart failureHemorrhagic strokeHospital medicineIschemic strokeMortalityMyocardial infarctionPopulation statistics ePublished: 18 January 2022 Issue Published: January 2022 Copyright & PermissionsCopyright © 2022 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...